GGiantBullStocks

Abeona Therapeutics Inc. (ABEO)

NASDAQ · Healthcare

$6.48-7.43%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$369.33M
P/E ratio
EPS
Volume
1,705,026
52-week high
52-week low
Open
$7.01
Day high
$7.07
Day low
$6.37

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$5.82M$71.18M$1.01
2024-$63.73M-$1.55
2023$3.5M-$54.19M-$2.53
2022$1.41M-$39.7M-$5.53
2021$3M-$84.94M-$21.57

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.

CEO
Vishwas Seshadri
Employees
226
Country
US
IPO date
Sep 19, 1980

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Abeona Therapeutics Inc.'s stock price today?
ABEO is trading at $6.48 as of Jul 20, 2026.
What is Abeona Therapeutics Inc.'s market cap?
Abeona Therapeutics Inc. (ABEO) has a market capitalization of $369.33M.
Does Abeona Therapeutics Inc. pay a dividend?
Abeona Therapeutics Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Abeona Therapeutics Inc. in?
Abeona Therapeutics Inc. operates in the Healthcare sector.